Symptom Monitoring App Use Associated With Medication Adherence Among Woman Survivors of Breast Cancer on Adjuvant Endocrine Therapy.

Autor:	Krukowski RA; Department of Public Health Sciences, University of Virginia Comprehensive Cancer Center and School of Medicine, Charlottesville, VA., Hu X; Department of Public Health Sciences, University of Virginia Comprehensive Cancer Center and School of Medicine, Charlottesville, VA.; Department of Radiation Oncology, Emory University, Atlanta, GA., Arshad S; Department of Health Policy and Management, Emory University, Atlanta, GA., Anderson JN; Department of Community and Population Health, University of Tennessee Health Science Center, Memphis, TN., Stepanski E; Ovation.io, Cambridge, MA., Vidal GA; West Cancer Center and the Lee S. Schwartzberg Research Institute, Germantown, TN.; College of Medicine, University of Tennessee Health Science Center, Memphis, TN., Schwartzberg LS; Renown Institute for Cancer and University of Nevada, Reno, NV., Graetz I; Department of Radiation Oncology, Emory University, Atlanta, GA.; Department of Health Policy and Management, Emory University, Atlanta, GA.
Jazyk:	angličtina
Zdroj:	JCO clinical cancer informatics [JCO Clin Cancer Inform] 2024 Dec; Vol. 8, pp. e2400179. Date of Electronic Publication: 2024 Dec 06.
DOI:	10.1200/CCI-24-00179
Abstrakt:	Purpose: Oral adjuvant endocrine therapy (AET) reduces the risk of cancer recurrence and death for women with hormone receptor-positive (HR+) breast cancer. Because of adverse symptoms and socioecologic barriers, AET adherence rates are low. We conducted post hoc analyses of a randomized trial of a remote symptom and adherence monitoring app to evaluate characteristics associated with higher app use, satisfaction, and how app use was associated with AET adherence. Methods: Patients prescribed AET were randomly assigned to receive one of three intervention conditions: app, app + feedback, or enhanced usual care. Baseline and 6-month follow-up surveys, app use, and pillbox-monitored AET adherence data for app and app + feedback participants were used. Logistic regression evaluated the association between sociodemographic/clinical characteristics and app utilization and satisfaction, and how app use was associated with AET adherence (>80%). Results: Overall, 163 women with early-stage HR+ breast cancer were included; 35.0% had high app use (≥75% of weeks enrolled). No sociodemographic characteristics were associated with app use. Satisfaction with the app was higher among those who were younger (88.9% for age 31-49 years v 54.9% for age 65+ years, P < .001), identified as White (76.8% v 60.1% for Black, P = .045), had lower health literacy (85.4% v 68.2% with higher health literacy, P = .017), or were nonurban residents (85.7% v 68.6% for urban, P = .021). Most participants (90.3%) with high app use were AET-adherent compared with 66.8% for those with lower app use ( P < .001). Conclusion: Use of a remote monitoring app was similar across sociodemographic characteristics, and more frequent app use was associated with a higher likelihood of 6-month AET adherence. Encouraging women to monitor medication adherence and communicate adverse symptoms could improve AET adherence.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu